Biopharmaceutical company Jazz Pharmaceuticals (Nasdaq: JAZZ) announced on Wednesday that it has entered a definitive agreement to acquire clinical-stage biotechnology company Redx Pharma's KRAS inhibitor program, expanding its targeted oncology therapies.
The deal involves a USD10m upfront payment to Redx, with the potential for additional payments of up to USD870m based on development, regulatory and sales milestones. Redx will also receive royalties on future net sales. The collaboration includes advancing candidates through IND-enabling studies, with Jazz taking charge of clinical development, regulatory activities, manufacturing and commercialisation. The acquisition aligns with the pursuit of novel treatments for colorectal, pancreatic and lung cancers.
As part of the agreement, Jazz will pay Redx for research and preclinical development activities to complete IND-enabling studies for both G12D selective and pan-KRAS molecules.
KRAS, the most frequently mutated oncogene, holds potential for treating various cancer types. The deal positions Jazz to explore orally bioavailable agents targeting KRAS mutations, extending beyond the G12C mutation.
Jazz Pharmaceuticals, headquartered in Dublin, Ireland, focuses on developing transformative medicines for serious diseases in neuroscience and oncology, with a global presence and a diverse portfolio of marketed medicines and novel candidates.
Redx Pharma (AIM: REDX) concentrates on discovering and developing targeted therapeutics for fibrotic diseases and cancer. With a strong track record, Redx's lead fibrosis product candidate, zelasudil (RXC007), is in Phase 2a trials for idiopathic pulmonary fibrosis, while the oncology candidate RXC004 aims to report Phase 2 data in H1 2024. The acquisition follows Redx's strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305) and collaborations with AstraZeneca and Jazz Pharmaceuticals.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration